Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

Medicine, Oncology, Pharmacology +17

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

María Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar et al. · Cancer Research · 2016 · 779 citations · Full text

Medicine, Cancer Biology, Oncology +17

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Ping Chen, Nathan V. Lee, Wenyue Hu et al. · Molecular Cancer Therapeutics · 2016 · 422 citations

Medicine, Oncology, Pharmacology +9

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

Rosaria Condorelli, Laura M. Spring, Joyce O’Shaughnessy et al. · Annals of Oncology · 2017 · 404 citations · Full text

Medicine, Cancer Biology, Oncology +16

Structures of thymidine kinase 1 of human and mycoplasmic origin

M. Welin, U. Kosinska, Nils-Egil Mikkelsen et al. · Proceedings of the National Academy of Sciences · 2004 · 149 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14